Insight journal - Dealtalk

Is Pfizer’s next acquisition target, Actavis?

Posted on 22 August 2014

Tags: , ,

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.

Pfizer may not get a great shot at buying AstraZeneca this fall--but it's preparing to give it a try.

That domicile is a key factor, of course, given Pfizer's ($PFE) desire for a deal with tax breaks on the side. Actavis ($ACT) moved its nominal headquarters to Dublin when it bought Warner Chilcott last year.

That deal--and its subsequent buyout of U.S.-based Forest Laboratories--also built up Actavis' business in branded pharmaceuticals. So in addition to the company's large portfolio of generic meds, Actavis would bring along a few notable brands, and some newly approved meds.

Source: FiercePharma

For further deal information visit Current Agreements (subscription required)



Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply